Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF20A | O95235 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.63 |
| ▸ | CLK1 | P49759 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2727490 | 1.00 | KIF20A (1.00) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL274836 | 0.88 | KIF20A (0.79) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL274837 | 0.88 | KIF20A (0.79) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL19193585 | 0.87 | KIF20A (0.78) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL2727786 | 0.86 | KIF20A (1.00) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL2727783 | 0.86 | KIF20A (1.00) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL2725053 | 0.85 | KIF20A (1.00) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL2725057 | 0.85 | KIF20A (1.00) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL17179249 | 0.83 | KIF20A (0.74) | KIF20AMEN1KMT2ANPC1DYRK1A | |
| SCHEMBL19192813 | 0.82 | KIF20A (0.69) | KIF20AMEN1KMT2ANPC1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | claimed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | claimed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | claimed |
| US-8703808-B2 | Use of derivatives of indoles for the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-22 | — | — | US | claimed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | claimed |
| EP-2445497-B1 | Use of derivatives of indoles for the treatment of cancer | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-8703808-B2 | Use of derivatives of indoles for the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | disclosed |
| CN-102481285-A | Use of derivatives of indole for the treatment of cancer | CENTRE NAT RECH SCIENT | 2012-05-30 | — | — | CN | disclosed |
| EP-2445497-A2 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150211-A2 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-29 | — | — | WO | disclosed |
| EP-2266562-A1 | Use of derivatives of indoles for the treatment of cancer | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF20A 871/4885MEN1 891/4885KMT2A 1470/4885 |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF20A 871/4885MEN1 891/4885KMT2A 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.